{"id":51812,"date":"2025-12-23T11:36:14","date_gmt":"2025-12-23T03:36:14","guid":{"rendered":"https:\/\/flcube.com\/?p=51812"},"modified":"2025-12-23T11:36:15","modified_gmt":"2025-12-23T03:36:15","slug":"iview-gvb-2001-gene-therapy-treats-first-poag-patient-successfully","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51812","title":{"rendered":"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully"},"content":{"rendered":"\n<p><strong>IVIEW Therapeutics Inc.<\/strong> announced the successful treatment of the <strong>first patient<\/strong> with <strong>primary open-angle glaucoma (POAG)<\/strong> using its self-developed gene therapy candidate <strong>GVB-2001<\/strong>. At the two\u2011week follow\u2011up, the patient reported <strong>no drug\u2011related adverse events<\/strong>, and a <strong>downward trend in intraocular pressure (IOP)<\/strong> has been observed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone-amp-product-profile\">Clinical Milestone &amp; Product Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>IVIEW Therapeutics Inc. (China-based)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GVB-2001<\/td><\/tr><tr><td><strong>Milestone<\/strong><\/td><td>First patient treated with POAG<\/td><\/tr><tr><td><strong>Follow\u2011up Period<\/strong><\/td><td>2 weeks<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>No drug\u2011related adverse events reported<\/td><\/tr><tr><td><strong>Efficacy Signal<\/strong><\/td><td>Intraocular pressure (IOP) trending downward<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>First\u2011in\u2011class gene therapy for POAG<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-breakthrough-technology-first-universal-poag-gene-therapy\">Breakthrough Technology: First Universal POAG Gene Therapy<\/h2>\n\n\n\n<p><strong>Key Differentiation:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Universal Applicability<\/strong>: World&#8217;s first POAG gene therapy that <strong>does not require genetic screening<\/strong>, potentially applicable to <strong>all POAG patients<\/strong><\/li>\n\n\n\n<li><strong>Vector Technology<\/strong>: Optimized <strong>self\u2011complementary adeno\u2011associated virus (scAAV)<\/strong> vector<\/li>\n\n\n\n<li><strong>Delivery Method<\/strong>: Single <strong>intracameral injection<\/strong> directly to trabecular meshwork<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Modulates cellular functions to <strong>enhance aqueous humor outflow<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Goal<\/strong>: Achieve <strong>rapid and sustained IOP control<\/strong> by intervening at disease pathology level<\/li>\n\n\n\n<li><strong>Clinical Impact<\/strong>: Reduces <strong>optic nerve damage risk at its source<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Market Insight<\/th><\/tr><\/thead><tbody><tr><td><strong>POAG Prevalence<\/strong><\/td><td><strong>80 million<\/strong> patients globally; <strong>15 million<\/strong> in China<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Topical eye drops (lifelong use); surgical options for advanced cases<\/td><\/tr><tr><td><strong>Gene Therapy Gap<\/strong><\/td><td>No approved gene therapies for POAG; one\u2011time treatment represents paradigm shift<\/td><\/tr><tr><td><strong>Market Size<\/strong><\/td><td>China glaucoma market exceeds <strong>$1.2 billion<\/strong> (2024), growing at 7% CAGR<\/td><\/tr><tr><td><strong>Competitive Advantage<\/strong><\/td><td>Universal patient eligibility vs. gene\u2011specific competitors (if any)<\/td><\/tr><tr><td><strong>Pipeline Position<\/strong><\/td><td>First\u2011in\u2011class asset with potential platform expansion to other glaucoma subtypes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-next-steps\">Strategic Outlook &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development<\/strong>: Dose\u2011escalation study ongoing; enrollment of additional patients planned for Q1\u202f2026<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: In\u2011house scAAV production platform enables cost\u2011effective scaling for commercial supply<\/li>\n\n\n\n<li><strong>Regulatory Path<\/strong>: Positive first\u2011patient data supports IND filing in US\/EU; potential <strong>orphan drug designation<\/strong> in select markets<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: Analysts project <strong>$500\u2011800 million<\/strong> peak global sales if Phase\u202f3 successful and approved<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Success in POAG opens pathway for IVIEW&#8217;s broader ophthalmic gene therapy pipeline<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding GVB-2001 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IVIEW Therapeutics Inc. announced the successful treatment of the first patient with primary open-angle glaucoma&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51813,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[66,3180],"class_list":["post-51812","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-gene-therapy","tag-iview-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"IVIEW Therapeutics Inc. announced the successful treatment of the first patient with primary open-angle glaucoma (POAG) using its self-developed gene therapy candidate GVB-2001. At the two\u2011week follow\u2011up, the patient reported no drug\u2011related adverse events, and a downward trend in intraocular pressure (IOP) has been observed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51812\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully\" \/>\n<meta property=\"og:description\" content=\"IVIEW Therapeutics Inc. announced the successful treatment of the first patient with primary open-angle glaucoma (POAG) using its self-developed gene therapy candidate GVB-2001. At the two\u2011week follow\u2011up, the patient reported no drug\u2011related adverse events, and a downward trend in intraocular pressure (IOP) has been observed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51812\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-23T03:36:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-23T03:36:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51812#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51812\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully\",\"datePublished\":\"2025-12-23T03:36:14+00:00\",\"dateModified\":\"2025-12-23T03:36:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51812\"},\"wordCount\":373,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51812#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2302.webp\",\"keywords\":[\"Gene therapy\",\"IVIEW Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51812#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51812\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51812\",\"name\":\"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51812#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51812#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2302.webp\",\"datePublished\":\"2025-12-23T03:36:14+00:00\",\"dateModified\":\"2025-12-23T03:36:15+00:00\",\"description\":\"IVIEW Therapeutics Inc. announced the successful treatment of the first patient with primary open-angle glaucoma (POAG) using its self-developed gene therapy candidate GVB-2001. At the two\u2011week follow\u2011up, the patient reported no drug\u2011related adverse events, and a downward trend in intraocular pressure (IOP) has been observed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51812#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51812\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51812#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2302.webp\",\"width\":1080,\"height\":608,\"caption\":\"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51812#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully - Insight, China&#039;s Pharmaceutical Industry","description":"IVIEW Therapeutics Inc. announced the successful treatment of the first patient with primary open-angle glaucoma (POAG) using its self-developed gene therapy candidate GVB-2001. At the two\u2011week follow\u2011up, the patient reported no drug\u2011related adverse events, and a downward trend in intraocular pressure (IOP) has been observed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51812","og_locale":"en_US","og_type":"article","og_title":"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully","og_description":"IVIEW Therapeutics Inc. announced the successful treatment of the first patient with primary open-angle glaucoma (POAG) using its self-developed gene therapy candidate GVB-2001. At the two\u2011week follow\u2011up, the patient reported no drug\u2011related adverse events, and a downward trend in intraocular pressure (IOP) has been observed.","og_url":"https:\/\/flcube.com\/?p=51812","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-23T03:36:14+00:00","article_modified_time":"2025-12-23T03:36:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51812#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51812"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully","datePublished":"2025-12-23T03:36:14+00:00","dateModified":"2025-12-23T03:36:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51812"},"wordCount":373,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51812#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2302.webp","keywords":["Gene therapy","IVIEW Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51812#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51812","url":"https:\/\/flcube.com\/?p=51812","name":"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51812#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51812#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2302.webp","datePublished":"2025-12-23T03:36:14+00:00","dateModified":"2025-12-23T03:36:15+00:00","description":"IVIEW Therapeutics Inc. announced the successful treatment of the first patient with primary open-angle glaucoma (POAG) using its self-developed gene therapy candidate GVB-2001. At the two\u2011week follow\u2011up, the patient reported no drug\u2011related adverse events, and a downward trend in intraocular pressure (IOP) has been observed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51812#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51812"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51812#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2302.webp","width":1080,"height":608,"caption":"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51812#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51812"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51812\/revisions"}],"predecessor-version":[{"id":51814,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51812\/revisions\/51814"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51813"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}